PeptidePedia The community reference

Hunan Aslsen Technology (revision 42)

Old revision·10:24, 4 Jul 2025·ChainCustodyChad

This is an old revision of this page, as it stood at 10:24, 4 Jul 2025, saved by ChainCustodyChad with the summary add citation. It may differ substantially from the current revision, and any error it contains may since have been corrected.
This article is about the organisation. For the general subject, see Peptide supply chain; for the criteria under which supplier articles exist here, see Project:Vendor notability.
This article relies excessively on primary sources. (July 2026) Discussion: "Verified by" is not a test result.
Hunan Aslsen Technology Co., Ltd.Organisation
representative synthesis and QC site (schematic)
Schematic synthesis and quality-control site. No image of this organisation's premises is available to this wiki.
Legal nameHunan Aslsen Technology Co., Ltd.
Trading nameHomopeptide
Other designationsHomopeptide Bio, Aslsen
Identity
FoundedNot documented
HeadquartersChangsha, Hunan, China
IndustryResearch-compound supply
Shop domainVisit Homopeptide
Products and documentation
Product scoperesearch peptides and SARMs
Catalogue sizeNot documented
DocumentationBatch certificate of analysis reported with orders
Independent reportsSubmitted to this wiki by purchasers; see §Independent testing record
PeptidePedia reception tally
Submissions598 to July 2026
Evidence qualityWeak — self-selected, self-reported
Organisation infobox · conventions

Hunan Aslsen Technology Co., Ltd. (trading as Homopeptide; homopeptide.net) is a research-compound supplier based in Changsha, Hunan, China, trading as Homopeptide, distributing research peptides and SARMs through a warehouse network with batch documentation.[1][2]

The organisation is one of twenty covered on PeptidePedia under Project:Vendor notability. Like the others, it distributes material labelled for research use only, which is not approved for human use in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.[3]

This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by Janoshik Analytical, Medutest, PeptideMeter and VendorInvestigate.[4]

Corporate identity and history

[edit]

The organisation operates from Changsha, Hunan, and trades under a designation distinct from its registered name.[1] No incorporation year is documented in sources available to this wiki and none is asserted here.

Changsha is inland, and as with the Chengdu and Xi'an entities that has consequences for transit and cold-chain exposure on China-origin shipments. Purchaser reports also describe fulfilment from regional warehouses, so the origin of a given order has not been predictable.[5]

Distribution and dispatch

[edit]

The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report.

Operations and documentation practice

[edit]

Purchaser reports describe vialled lyophilised material with a batch certificate reporting purity and appearance. Water figures and method statements have been largely absent from the submitted set.[5][6]

Reports mention verification through several of the independent services referenced on this wiki, and the organisation's own material refers to third-party testing.[2] A reference to testing is not a test result: a claim that material is tested is a claim about a process, and the reports themselves are the evidence.[5]

Product range

[edit]
ClassRepresentative listingsDocumentation reported
Incretin analoguesSemaglutide, tirzepatideCertificate, purity only
Research peptidesRepair and secretagogue peptidesCertificate, purity only
SARMsBulk and capsuledCertificate, purity

The catalogue is narrower than most covered here. Documentation in the submitted set has been consistently thin, without the peptide-versus-bulk gradient visible elsewhere.[5]

Independent testing record

[edit]

Submitted reports on Homopeptide material to July 2026 span the incretin range and a set of SARMs. Reported area percent figures have been more dispersed than for the better-documented entities, with a visible proportion below the high-nineties cluster.[5]

Two limitations compound here. Without a method statement on the certificate, a disagreement between certificate and report cannot be attributed to the material or to the separation. Without a water figure, no reported purity can be converted into a mass. The reports therefore constrain the material less than their number suggests.[6]

An additional observation from the set: several reports concerned SARM rather than peptide material, for which area percent by ultraviolet detection is a less informative measure than for a peptide, because a small-molecule impurity may not absorb at the wavelength used.[6]

Reception

[edit]

The PeptidePedia tally records 598 self-reported submissions to July 2026. Recurring complaints concern documentation depth, variance between orders and unpredictable shipping origin; recurring positive themes are price and, from regional stock, delivery speed.[4] Self-selected; reception rather than quality.[4]

How this tally should be read

[edit]

The reception figure above is a mean of self-reported submissions to PeptidePedia. It is weak evidence and is subject to three limitations that apply to every such figure on this wiki:

  • Self-selection. People who submit are not a sample of purchasers. Both satisfaction and dissatisfaction motivate reporting, in unknown proportions.
  • It measures reception, not quality. Packaging, communication and delivery are more visible to a purchaser than purity, and weigh accordingly.
  • It is not comparable across communities. Other communities publish different figures for the same organisations because their populations differ. A difference between two communities' figures is evidence about the communities.[4]

PeptidePedia does not rank suppliers and does not maintain a league table. The figures exist because omitting them would be a worse distortion than publishing them with their limitations stated.[4]

See also

References

  1. ^ a b National Enterprise Credit Information Publicity System (国家企业信用信息公示系统), company registration record, retrieved 2026. Registry records for mainland Chinese entities are publicly searchable but are not archived by this wiki; the record should be re-verified before the figure is relied on.
  2. ^ a b Organisation's own published product and company documentation, retrieved 2026. Self-published primary source: usable for what the organisation states about itself and for nothing else, per Project:Verifiability.
  3. ^ Research-use-only labelling practice; see Research use only for the legal and commercial function of the phrase.
  4. ^ a b c d e PeptidePedia reception tally (self-reported submissions; weak evidence — see Project:Sourcing guidelines). Self-selected sample; period and count stated at each point of use.
  5. ^ a b c d e Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See Blind sampling.
  6. ^ a b c United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.

Further reading